Profile
Stephen Wooding has held director positions at CellProtect Nordic Pharmaceuticals AB and XNK Therapeutics AB.
Stephen Wooding active positions
| Companies | Position | Start |
|---|---|---|
XNK Therapeutics AB
 XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | Director/Board Member | 04/10/2021 |
CellProtect Nordic Pharmaceuticals AB
 CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
XNK Therapeutics AB
XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | Health Technology |
CellProtect Nordic Pharmaceuticals AB
CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | Health Technology |
- Stock Market
- Insiders
- Stephen Wooding
